News

Featuring Philips’ latest-generation flat detector technology, advanced imaging algorithms, and personalized user profiles, the new system delivers superior image quality, dose efficiency, and workflow customization.

Program participants will be provided with easy access to supporting resources such as the guideline and ECDP documents, the ASCVD Risk Estimator, and CardioSmart patient education materials at the point of care.

The LimFlow System for Transcatheter Arterialization of Deep Veins (TADV) is designed to reestablish blood flow in deep veins for “no-option” CLTI patients. The therapy is designed to save patients’ legs from major amputation.

A team of scientists took their research to new heights by leveraging the International Space Station (ISS) National Laboratory to study microgravity’s effects on heart cells.

LimFlow’s FDA approval follows publication of results from the PROMISE II Multicenter Prospective Study, which found that the therapy enabled most patients treated to keep their leg and experience wound healing.

The study, involving more than 90,000 patients, was designed to assess at a national level the incremental impact of adding FFRCT to a CCTA-first (Coronary Computed Tomography Angiography) diagnostic pathway to evaluate and manage CAD.

FastWave seeks to address the challenges of artery calcification, a significant predictor of adverse cardiac events, through differentiated intravascular lithotripsy platforms.

Obesity currently affects about 42% of the U.S. population, an increase by almost 10% from the preceding decade.

"Less than 40% with atherosclerotic CVD were on statins at the correct guideline-recommended intensity, and nearly 1 in 4 were on no statins at all,” said Ann Marie Navar, MD, PhD.

Three new codes (effective October 1, 2023) allow facilities to report a short-term external heart pump positioned in the descending thoracic aorta.